ID
62
Cancer Name
Breast Lobular Carcinoma – Extension
Main Grouping
Reproductive
Organ System
Breast
Cell Origin
Lobular epithelial cells
Pathways Affected
Invasive lobular carcinoma involves a pathway landscape dominated by the CDH1/E-cadherin loss enabling single-file invasion, estrogen receptor-alpha (ERα)/FOXA1 transcriptional program driving proliferation in essentially 100 percent of classic ILC, the PI3K/AKT/mTOR pathway activated in over 60 percent of ILC through PIK3CA/PTEN/AKT1 alterations, IGF1R signaling specifically activated by E-cadherin loss, and the Wnt/beta-catenin and RAS/MAPK/ERK signaling pathways.
The CDH1/E-cadherin loss/IGF1R pathway is the pathognomonic molecular mechanism of ILC: CDH1 loss in approximately 90 to 95 percent of ILC removes E-cadherin-mediated cell adhesion disrupting the epithelial adherens junction complex (E-cadherin/alpha-catenin/beta-catenin/p120-catenin); loss of E-cadherin specifically and uniquely activates IGF1R receptor availability for ligand binding — E-cadherin normally sequesters IGF1R at the cell surface preventing IGF1/IGF2-mediated activation, so CDH1 loss releases IGF1R for ligand binding creating constitutive IGF1R/PI3K/AKT/mTOR and IGF1R/RAS/MAPK/ERK signaling in ILC cells confirmed in published research; E-cadherin loss also causes cytoplasmic p120 catenin accumulation and ROCK kinase/RhoA-mediated cytoskeletal reorganization enabling the single-file discohesive migration; genistein inhibits IGF1R signaling and the PI3K/AKT pathway downstream of IGF1R in breast cancer cell models; quercetin inhibits IGF1R/PI3K/AKT in breast cancer cell models.
The ERα/FOXA1/PR estrogen signaling pathway drives proliferation in approximately 95 percent of ILC — a uniquely high ER-positivity rate unmatched by any other breast cancer subtype: ERα drives transcription of cyclin D1 (CCND1), progesterone receptor (PGR), GREB1, TFF1, and a set of ILC-specific genes including WNT4 that are uniquely estrogen-regulated in ILC versus IDC cells; FOXA1 is the pioneer transcription factor that opens chromatin at ERα binding sites — FOXA1 mutations (~10-14%, ILC-enriched) create gain-of-function neo-transcriptional programs and are associated with endocrine resistance; genistein from soybeans competes with estradiol for ERα/ERβ binding — at high doses genistein inhibits MCF-7 ER-positive cell proliferation through ERα regulation and apoptosis confirmed (PMC4079435); genistein preferentially binds ERβ (binding affinity ~20-fold higher for ERβ than ERα) and ERβ activation opposes ERα-driven proliferation; at high concentrations genistein inhibits ERα mRNA expression confirmed (PMC3116930) — directly targeting the dominant ERα/FOXA1 proliferative program in ILC.
The PI3K/AKT/mTOR pathway is the most frequently mutated signaling pathway in ILC with collectively over 60 percent of cases harboring PIK3CA activating mutations (~35-50%), PTEN loss (~25%), or AKT1 mutations (~5%): PIK3CA E545K and H1047R hotspot mutations create constitutively active PI3K-alpha driving PIP3/AKT/mTOR/S6K1 signaling; PTEN loss removes PIP3 phosphatase creating constitutive AKT activation; AKT1 E17K mutations create constitutively membrane-targeted AKT1; all three mechanisms converge on mTORC1 activation driving ribosome biogenesis, protein synthesis, and cap-dependent translation; curcumin inhibits PI3K/AKT and mTOR in ER-positive breast cancer cell models; quercetin inhibits PI3K/AKT/mTOR in breast cancer cell models; genistein inhibits PI3K/AKT in ER-positive breast cancer cell models.
The WNT/beta-catenin pathway is uniquely and specifically activated in ILC through ER-driven WNT4 transcription: WNT4 is a uniquely estrogen-regulated gene in ILC cell lines (MDA-MB-134 and SUM44PE) confirmed — WNT4 is required for estrogen-induced proliferation in ILC cells, and WNT4 knockdown blocks estrogen-induced growth in ILC cell lines (PMC5028957); E-cadherin loss releases beta-catenin from the E-cadherin/beta-catenin complex potentially enabling nuclear beta-catenin/TCF4 Wnt target gene transcription; curcumin inhibits Wnt/beta-catenin through downregulation of DVL, beta-catenin, and cyclin D1 in breast cancer cell models; genistein inhibits Wnt/beta-catenin signaling in breast cancer cell models; quercetin inhibits Wnt/beta-catenin in breast cancer cell models targeting both E-cadherin loss-driven beta-catenin release and ER/WNT4-driven Wnt program.
Description
Invasive lobular carcinoma (ILC) is the second most common invasive breast cancer subtype, accounting for approximately 10 to 15 percent of all invasive breast cancers globally. In the United States, with approximately 310,000 new invasive breast cancer cases projected for 2024, ILC accounts for approximately 31,000 to 46,500 new cases annually. Globally, ILC accounts for approximately 250,000 to 370,000 new cases annually. The incidence of ILC has been increasing over recent decades, with some attributing this trend to postmenopausal hormone therapy use — ILC has a particularly strong association with combined estrogen-progestin hormone replacement therapy use compared to IDC.
ILC is predominantly a disease of older women with a median age at diagnosis of approximately 60 to 65 years — slightly older than IDC — and is exceedingly rare before age 40. ILC is almost exclusively found in women; male ILC is extraordinarily rare. The 5-year relative survival for ILC across all stages is approximately 87 to 92 percent, comparable to IDC; however, ILC tends to have paradoxically better early outcomes but worse late outcomes compared to IDC, reflecting its indolent biology and the late recurrence pattern at 10 to 20 years post-diagnosis.
The molecular biology of ILC is fundamentally distinct from IDC: ILC is universally ER-positive (~95%), HER2-non-amplified (~93-95%), has a low proliferative index (Ki-67 ~10-20%), and is defined by CDH1/E-cadherin loss in approximately 90 to 95 percent of cases; ILC clusters in the luminal A molecular subtype in approximately 80 to 90 percent of cases, with luminal B (~5-10%) and rarely HER2-enriched or triple-negative; PIK3CA/PTEN/AKT1 pathway alterations occur in over 60 percent of ILC collectively; FOXA1 mutations (~10-14%) are enriched in ILC versus IDC; the distinctive ERBB2 somatic point mutations (~5-7%) in ILC are distinct from ERBB2 gene amplification and activate the HER2 kinase domain.
Published laboratory research documents genistein from soybeans inhibiting MCF-7 human ER-positive breast cancer cell growth in a concentration-dependent manner — inhibiting proliferation by 13 to 77 percent at 24 to 48 hours at doses of 50 to 200 μM through ERα expression regulation and apoptosis induction (PMC4079435) — directly relevant to ILC because ILC is approximately 95 percent ER-positive with FOXA1-driven ERα transcriptional programs as the dominant growth driver; genistein in T47D and MCF-7 ER-positive breast cancer cells inhibiting growth and inducing apoptosis through caspase-3 activation (PMC3116930); and genistein in MCF-7/ERβ1 cells inhibiting proliferation greater than in parental cells and confirmed in vivo in mice (PMC6241715) — targeting the ERβ/ERα balance that is uniquely relevant to ILC's high ERα expression and FOXA1-driven transcriptional program.
Plant-Based Description
Whole-food plant-based dietary patterns provide phytochemicals with documented activity in ER-positive breast cancer cell lines directly applicable to invasive lobular carcinoma through its dominant ER-alpha/FOXA1 transcriptional program (~95% ER-positive) and PI3K/AKT pathway activation (>60% of cases). Genistein from soybeans inhibited MCF-7 human ER-positive breast cancer cell growth in a concentration-dependent manner inhibiting proliferation by 13 to 77 percent at 24 to 48 hours through ERα expression regulation and apoptosis induction confirmed (PMC4079435) — directly targeting the dominant ERα-driven proliferative program in ILC; genistein inhibited ER-positive T47D and MCF-7 cell growth and induced apoptosis through caspase-3 activation and ERα mRNA reduction (PMC3116930); genistein inhibited MCF-7/ERβ1 cell proliferation with greater efficacy than parental cells and confirmed in vivo in mice (PMC6241715) targeting the ERβ/ERα balance relevant to ILC; curcumin, quercetin, resveratrol, and sulforaphane from plant foods all inhibit PI3K/AKT/mTOR, NF-kB, and Wnt/beta-catenin in ER-positive breast cancer cell models; flaxseed-derived lignans provide enterolactone and enterodiol with documented anti-proliferative activity in ER-positive breast cancer cell models.
Plant Chemistry Detail
Genistein from soybeans has the most directly documented anti-ER-positive breast cancer cell line activity through multiple confirmed published studies, directly relevant to ILC's ~95% ER-positivity.
In the first confirmed study (PMC4079435) using MCF-7 human ER-positive breast cancer cells: genistein was tested at doses of 50, 100, 150, and 200 μmol/L for 24, 48, and 72 hours; genistein inhibited MCF-7 cell growth in a concentration-dependent manner confirmed; at 48 hours reductions of 13%, 29%, 55%, and 77% were observed for 50, 100, 150, and 200 μmol/L genistein respectively compared to controls; genistein regulated ERα expression confirmed — downregulating ERα to reduce estrogen-driven proliferative signaling; genistein induced apoptosis in MCF-7 cells confirmed. This directly targets the dominant ERα transcriptional growth program in ILC, where ER-alpha drives cyclin D1 (CCND1), WNT4, GREB1, TFF1, and a unique set of ILC-specific estrogen-regulated genes confirmed in the ILC cell lines MDA-MB-134 and SUM44PE (PMC3955299).
In the second confirmed study (PMC3116930) using T47D and MCF-7 ER-positive breast cancer cells: genistein inhibited cancer cell growth in ER-positive cell lines confirmed; genistein induced apoptosis through caspase-3 activity confirmed; genistein inhibited ERα mRNA expression confirmed; genistein increased the ratio of ERβ to ERα confirmed — which is directly relevant to ILC biology because ERβ opposes ERα-driven proliferation through ERβ-specific gene programs that promote differentiation and inhibit growth; genistein derivatives showed IC50 values of 1 to 2.5 μM in T47D and MCF-7 cells with consistent antiproliferative and apoptotic activity.
In the third confirmed study (PMC6241715) using MCF-7/ERβ1 cells with confirmed in vivo extension: genistein inhibited MCF-7/ERβ1 cell proliferation to a greater extent than parental MCF-7 at high concentrations confirmed; genistein inhibited MDA-MB-231/ERβ1 cells at high doses confirmed; in vivo studies confirmed dietary genistein effects on MCF-7/ERβ1 and MDA-MB-231/ERβ1 cell-implanted mice — confirming in vivo anti-tumor activity.
Quercetin from onions and kale inhibits PI3K/AKT/mTOR, NF-kB, and Wnt/beta-catenin in ER-positive breast cancer cell models — targeting the PI3K/AKT pathway activated in over 60 percent of ILC through PIK3CA/PTEN/AKT1 mutations; quercetin reduces IGF1R signaling in breast cancer cell models targeting the CDH1-loss-activated IGF1R axis unique to ILC. Curcumin from turmeric inhibits PI3K/AKT, mTOR, NF-kB, Wnt/beta-catenin, and FOXO/FOXA1 in ER-positive breast cancer cell models targeting the dominant ILC oncogenic pathways; curcumin also inhibits HDAC and DNMT targeting CDH1 promoter methylation-based E-cadherin silencing in breast cancer cell models. Resveratrol from grapes inhibits PI3K/AKT, Wnt/beta-catenin, NF-kB, and activates SIRT1/AMPK in ER-positive breast cancer cell models. Sulforaphane from cruciferous vegetables activates Nrf2/ARE and inhibits NF-kB and HDAC in breast cancer cell models — targeting HDAC-driven CDH1 epigenetic silencing. Flaxseed-derived lignans (secoisolariciresinol, matairesinol) are metabolized by gut microbiome to enterolactone and enterodiol, which competitively inhibit ERα in ER-positive breast cancer cell models at high tissue concentrations; published research documents flaxseed lignan intake association with anti-proliferative effects on ER-positive breast cancer in clinical data. Daidzein from soybeans inhibits proliferation in ER-positive breast cancer cells at high concentrations through ERα/ERβ competition and PI3K/AKT inhibition in published research.
Nutritional Focus
Nutritional focus in invasive lobular carcinoma research is led by genistein from soybeans and edamame with directly documented anti-ER-positive breast cancer cell line activity across three confirmed published studies — all highly relevant to ILC's ~95% ER-positive prevalence: genistein inhibiting MCF-7 ER-positive breast cancer cell proliferation in a concentration-dependent manner by 13 to 77 percent at 24 to 48 hours through ERα expression regulation and apoptosis induction confirmed (PMC4079435) — directly targeting the dominant ERα/FOXA1 transcriptional growth program in ILC; genistein inhibiting growth and inducing apoptosis through caspase-3 activation and ERα mRNA reduction in T47D and MCF-7 ER-positive breast cancer cells while increasing the ERβ/ERα ratio (PMC3116930) — the ERβ to ERα balance being directly relevant to ILC where high ERα drives proliferation and ERβ opposes it; genistein inhibiting MCF-7/ERβ1 proliferation with greater efficacy than parental cells and confirmed in vivo in mice (PMC6241715); daidzein from soybeans exhibiting anti-proliferative effects in ER-positive breast cancer cells at high concentrations through ERα/ERβ competition; curcumin from turmeric inhibiting PI3K/AKT/mTOR and DNMT/HDAC in ER-positive breast cancer cell models — targeting both the PIK3CA/PTEN/AKT1 pathway activated in over 60 percent of ILC and CDH1 promoter methylation-based E-cadherin silencing; quercetin from onions and kale inhibiting PI3K/AKT/mTOR, IGF1R, NF-kB, and Wnt/beta-catenin in breast cancer cell models targeting the CDH1-loss-activated IGF1R axis unique to ILC and the PI3K/AKT pathway; flaxseed-derived enterolactone and enterodiol providing competitive ERα inhibition in ER-positive breast cancer cell models relevant to ILC's universal ER-positivity; EGCG from green tea inhibiting DNMT targeting CDH1 promoter methylation; sulforaphane activating Nrf2/ARE and inhibiting HDAC targeting CDH1 epigenetic silencing; and dietary fiber producing butyrate/SCFAs that inhibit HDAC activity targeting CDH1 promoter methylation-based E-cadherin silencing documented in ILC.
Research Notes
ILC epidemiology: ~10-15% of all invasive breast cancers; ~31,000-46,500 new US cases annually; ~250,000-370,000 global new cases annually; median age ~60-65 years; predominantly women; bilateral ~6-19% (vs IDC ~3-5%). 5-year OS ~87-92%; better early but worse late outcomes vs IDC; late recurrence 10-20 years post-diagnosis. Incidence increasing — association with combined estrogen-progestin HRT. Histology: single-file (Indian file) infiltrative growth; no gland formation; discohesive cells; E-cadherin negative; cytoplasmic p120; ER+~95%, PR+~70%, HER2-amp ~5-7%, low Ki-67 ~10-20%, GCDFP-15+. Molecular: CDH1 mutations/deletions ~51-65% (truncating frameshift/nonsense predominant); CDH1 loss ~90-95% overall (mutation + LOH + methylation + deletion); CDH1 at 16q22.1; PIK3CA ~35-50% (E545K, H1047R hotspots); FOXA1 mutations ~10-14% (ILC-enriched); TBX3 ~12%; RUNX1 ~10%; PTEN loss ~25%; AKT1 ~5%; ERBB2 somatic point mutations ~5-7% (distinct from amplification); FGFR1 copy number gain ~14%; CCND1 amplification ~27%; PI3K/AKT/PTEN collectively >60%. CDH1 loss activates IGF1R receptor availability confirmed. Germline CDH1 = HDGC-HLBC syndrome. ILC ~95% luminal A, ~5-10% luminal B. WNT4 uniquely estrogen-regulated in ILC cell lines MDA-MB-134/SUM44PE and required for estrogen-induced proliferation (PMC5028957). ILC cell lines: MDA-MB-134-VI (MM134), SUM44PE, MDA-MB-330, BCK4. Genistein MCF-7 ER-positive (PMC4079435): concentration-dependent 13-77% growth inhibition 24-48h; ERα regulation; apoptosis induction. Genistein T47D/MCF-7 (PMC3116930): IC50 1-2.5 μM derivatives; caspase-3 activity; ERα mRNA reduction; ERβ/ERα ratio increase. Genistein MCF-7/ERβ1 (PMC6241715): greater proliferation inhibition; in vivo mice confirmed.
Notes Visibility
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Cabbage,Blueberry,Pomegranate,Grape,Raspberry,Strawberry,Apple,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Black Rice,Walnut,Almond,Brazil Nut,Flaxseed,Pumpkin Seeds,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Cremini,Portobello,Lions Mane,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Celery, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-a,vitamin-b9,vitamin-b6,selenium,zinc,magnesium,calcium,potassium,iron,genistein,daidzein,curcumin,quercetin,egcg,resveratrol,secoisolariciresinol,beta-carotene,anthocyanins,beta-glucans,dietary-fiber
